Viatris, Inc. (VTRS)

Viatris's stock (VTRS) surged approximately 56% in the 12 months leading up to March 2026, outperforming the NYSE Arca Pharmaceutical Index. Recent financial events include the Q4 2025 earnings release on February 26, 2026, where Viatris reported revenues of $3.7 billion and adjusted EPS of $0.57, exceeding analyst estimates. The company also announced the completion of an enterprise-wide strategic review, anticipating $650 million in total cost savings over the next three years. Additionally, in February 2026, Viatris took a non-cash $2.9 billion goodwill impairment charge as part of its strategic review.

While specific detailed patterns of demand seasonality for Viatris's products are not extensively outlined, the company's 2026 guidance indicates an expectation for higher revenue and earnings in the second half of the year, partly attributed to product launches and seasonality. Viatris's global, flexible, and diverse supply chain is designed to manage risks of disruption and ensure supply reliability, even during periods of significant demand volatility.

Viatris Inc. is a global healthcare company formed in November 2020 through the merger of Mylan and Pfizer's Upjohn business, aiming to provide access to medicines, advance sustainable operations, and develop innovative solutions. The company has a diverse portfolio, including various key products and brands, covering a wide range of therapeutic areas and has identified dermatology, ophthalmology, and gastroenterology as key areas for future innovations.

Viatris has a substantial global presence, operating in over 165 countries and territories, segmented into Developed Markets, Greater China, JANZ, and Emerging Markets. The company maintains three global centers and operates 27 manufacturing sites globally.

Viatris has received positive recognition for its workplace and sustainability efforts, including being named to Forbes' list of the World's Best Employers 2025 for the fifth consecutive year. The company was also included in TIME's list of World's Most Sustainable Companies 2024 and Forbes' list of World's Top Companies for Women 2024. However, its predecessor company, Mylan, faced reputation challenges due to pricing controversies, particularly concerning the EpiPen.

Viatris Inc. has a predominantly institutional ownership structure, with institutional owners holding 76.9% of the outstanding stock as of December 2025. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and Price T Rowe Associates Inc /md/.